This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

66/100

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Genetics

Topic: Amyloid, tau and blood-test diagnosis

Within-person changes in CSF biomarkers were also compared with changes in cortical PiB binding and progression to a CDR higher than 0 at follow-up. Results While there were no consistent longitudinal patterns in Aβ40 (P = .001-.97), longitudinal reductions in Aβ42 were observed in some individuals as early as early middle age (P ≤ .05) and low Aβ42 levels were associated with the development of cortical PiB-positive amyloid plaques (area under receiver operating characteristic curve = 0.9352; 95% CI, 0.8895-0.9808), especially in mid middle age (P Conclusions and relevance Longitudinal CSF biomarker patterns consistent with AD are first detectable during early middle age and are associated with later amyloid positivity and cognitive decline.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Sutphen, C. L., Jasielec, M. S., Shah, A. R., Macy, E. M., Xiong, C., Vlassenko, A. G., et al. (2015). Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age. JAMA neurology. https://doi.org/10.1001/jamaneurol.2015.1285

Vancouver

Sutphen CL, Jasielec MS, Shah AR, Macy EM, Xiong C, Vlassenko AG, et al. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age. JAMA neurology. 2015. doi:10.1001/jamaneurol.2015.1285. PMID: 26147946.

BibTeX

@article{sutphen2015-26147946,
  author  = {Sutphen, C. L. and Jasielec, M. S. and Shah, A. R. and Macy, E. M. and Xiong, C. and Vlassenko, A. G. and Benzinger, T. L. and Stoops, E. E. and others},
  title   = {{Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age}},
  journal = {JAMA neurology},
  year    = {2015},
  doi     = {10.1001/jamaneurol.2015.1285},
  pmid    = {26147946},
  url     = {https://doi.org/10.1001/jamaneurol.2015.1285}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Within-person changes in CSF biomarkers were also compared with changes in cortical PiB binding and progression to a CDR higher than 0 at follow-up.
Results While there were no consistent longitudinal patterns in Aβ40 (P = .001-.97), longitudinal reductions in Aβ42 were observed in some individuals as early as early middle age (P ≤ .05) and low Aβ42 levels were associated with the development of cortical PiB-positive amyloid plaques (area under receiver operating characteristic curve = 0.9352; 95% CI, 0.8895-0.9808), especially in mid middle age (P < .001).

Why it matters

This cohort study found that changes in a spinal fluid marker of amyloid begin as early as early middle age and are linked to later amyloid buildup and cognitive decline. It may help identify people at risk earlier, but it does not show that any treatment or prevention works.

New to this subject? Start with our plain-English guide: Genetics →

Study details

Study designcohort study
Participants169
Evidence strengthModerate

How this study scored 66/100

Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for effect reported and randomised / blinded because the record does not state it.

Component	Points	Why
Journal tier	9 / 10	Tier 2 — leading specialty journal (JAMA neurology)
Journal's citation record	2 / 4	JAMA Neurology: journal h-index 235 (OpenAlex, 2026-10-29)
Study design	7 / 12	A cohort study following people over time
Strength of evidence	3 / 5	Rated “moderate” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	1 / 5	2015 — within 20 year(s) of the newest study here
Sample size	2 / 4	169 participants
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	3 / 3	Studied in people (participant count stated)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	5 / 7	Cited 297 times (OpenAlex, 2026-10-10)
Citations per year	4 / 5	22.8 citations a year over 13 year(s) since 2015
Impact for its field and year	5 / 6	Cited 24.9× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	3 / 6	Cited by 21 other studies in this library
Still being cited	2 / 4	Cited 48 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	4 / 4	Last-listed author Anne M. Fagan: h-index 122 (OpenAlex, whole career)
Institution's track record	2 / 3	Washington University in St. Louis: institution h-index 1,962 (OpenAlex)
Multi-centre collaboration	2 / 3	OpenAlex lists 5 institution(s) in 3 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 26147946)
Free to read	0 / 2	Behind a paywall — scores zero
Total	66 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 25.

Later studies that cite this one

21 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Genetics

Also tagged “biomarkers”

821 studies in the library carry the topic tag “biomarkers”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 821 tagged studies.

Similar studies

More on Genetics

See all studies in Genetics →